Understanding the role of mutations in therapeutic decision making for chronic myeloid leukemia.

Abstract excerpt

In patients with chronic myeloid leukemia (CML) resistant to imatinib, resistance is commonly associated with mutations in the BCR-ABL protein. Approximately 85% to 90% of resistance-associated mutations occur within the ABL kinase domain, and confer resistance either directly, by blocking imatinib binding, or indirectly, by altering the conformation of BCR-ABL. The degree of resistance depends on the mutation,...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Dasatinib
• Share to Drug Resistance, Neoplasm
• Share to Fusion Proteins, bcr-abl